Vecchi M, Cattaneo M, de Franchis R, Mannucci P M
A. Bianchi Bonomi Hemophilia and Thrombosis Centre, University of Milan, Italy.
Int J Clin Lab Res. 1991;21(2):165-70. doi: 10.1007/BF02591637.
A large number of hemostasis measurements complications were performed in 20 patients with inflammatory bowel disease; whose changes have been associated with an increased risk of thromboembolic. Of the 20 patients, 9 (45%) had one or more changes suggestive of activation of the hemostatic system. Such changes were more frequently observed in patients with active disease. Two patients had changes in the fibrinolytic system (high plasminogen activator inhibitor-1 levels) and 2 in the natural anticoagulants (low antithrombin III activity). Nine patients had increased plasma fibrinogen levels and 6 patients had slightly increased levels of anticardiolipin antibodies. Most of the changes observed were not related to the type, location or activity of the disease. These data show that various biochemical abnormalities may be found in patients with inflammatory bowel disease, which may account for their increased risk of thrombosis, and suggest that multiple mechanisms may interact in determining such complications.
对20例炎症性肠病患者进行了大量止血测量并发症检查;这些变化与血栓栓塞风险增加有关。在这20例患者中,9例(45%)有一项或多项提示止血系统激活的变化。此类变化在活动性疾病患者中更常见。2例患者纤溶系统有变化(纤溶酶原激活物抑制剂-1水平升高),2例患者天然抗凝剂有变化(抗凝血酶III活性降低)。9例患者血浆纤维蛋白原水平升高,6例患者抗心磷脂抗体水平略有升高。观察到的大多数变化与疾病的类型、部位或活动度无关。这些数据表明,炎症性肠病患者可能存在各种生化异常,这可能解释了他们血栓形成风险增加的原因,并提示多种机制可能相互作用导致此类并发症。